Tag: endometrialCancer

Articles

• Foods to eat and avoid during tamoxifen treatment
• Gynecological side effects of tamoxifen

News

07/22/22

Mortality after some second cancers may be higher for breast cancer survivors

12/09/12

Tamoxifen treatment for 10 years helps prevent late recurrence

04/18/12

Breast cancer survivors at higher risk of new breast tumors

07/17/11

Increasing aromatase inhibitor side effects make tamoxifen attractive

Studies

• The association between breast cancer and lung cancer: a bidirectional Mendelian randomization study Cite
  Li X, Liu J, Zhang J, Wang Y, He J, Zhang H. The association between breast cancer and lung cancer: a bidirectional Mendelian randomization study. Scientific Reports. Springer Science and Business Media LLC; 2024; 14 10.1038/s41598-024-76314-z
• Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers Cite
  Allen I, Hassan H, Walburga Y, Huntley C, Loong L, Rahman T, et al. Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2024; 10.1200/jco.24.01146
• Incidence of endometrial cancer in BRCA mutation carriers Cite
  Kotsopoulos J, Lubinski J, Huzarski T, Bychkovsky BL, Moller P, Kim RH, et al. Incidence of endometrial cancer in BRCA mutation carriers. Gynecologic Oncology. Elsevier BV; 2024; 189:148-155 10.1016/j.ygyno.2024.07.687
• Second primary malignancies in women with breast cancer Cite
  Chen C, Tseng J, Amersi F, Silberman AW. Second primary malignancies in women with breast cancer. Journal of Surgical Oncology. Wiley; 2024; 10.1002/jso.27785
• P-317 Risk of endometrial polyps and hyperplasia after tamoxifen treatment in women with breast cancer: a population-based study in Taiwan Cite
  Hsu C, Eing-Mei T, Hui-min H. P-317 Risk of endometrial polyps and hyperplasia after tamoxifen treatment in women with breast cancer: a population-based study in Taiwan. Human Reproduction. Oxford University Press (OUP); 2024; 39 10.1093/humrep/deae108.682
• Association of Levonorgestrel-Releasing Intrauterine Device with Gynecologic and Breast Cancers: National Cohort Study in Sweden Cite
  Yi H, Zhang N, Huang J, Zheng Y, Hong Qh, Sundquist J, et al. Association of Levonorgestrel-Releasing Intrauterine Device with Gynecologic and Breast Cancers: National Cohort Study in Sweden. American Journal of Obstetrics and Gynecology. Elsevier BV; 2024; 10.1016/j.ajog.2024.05.011
• Abstract PO3-11-10: Second primary non-breast cancers in young breast cancer survivors Cite
  Zhang B, Brantley K, Rosenberg S, Kirkner G, Collins L, Ruddy K, et al. Abstract PO3-11-10: Second primary non-breast cancers in young breast cancer survivors. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:PO3-11-10-PO3-11-10 10.1158/1538-7445.sabcs23-po3-11-10
• Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen? Cite
  Iatrakis G, Zervoudis S, Sarella A, Bothou A, Tsikouras P, Paschopoulos M, et al. Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen?. Review of Clinical Pharmacology and Pharmacokinetics - International Edition. PHARMAKON-Press; 2024; 38:7-9 10.61873/oefm7580
• Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study Cite
  Pla-Juher H, Pardo M, Izquierdo ÀJ, Darder E, Carbó A, Munté E, et al. Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study. Clinical and Translational Oncology. Springer Science and Business Media LLC; 2023; 26:1033-1037 10.1007/s12094-023-03312-4
• Abstract 7321: Second primary cancer risks following breast cancer in BRCA1/2 pathogenic variant carriers Cite
  Allen I, Hassan H, Walburga Y, Huntley C, Loong L, Rahman T, et al. Abstract 7321: Second primary cancer risks following breast cancer in BRCA1/2 pathogenic variant carriers. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:7321-7321 10.1158/1538-7445.am2024-7321
• Abstract 992: The impact of tamoxifen on autophagic and epigenetic regulation in endometrial cancer Cite
  Thota S, Begum R, Chintala N, Pandit A, Sapkota B, Francis J. Abstract 992: The impact of tamoxifen on autophagic and epigenetic regulation in endometrial cancer. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:992-992 10.1158/1538-7445.am2024-992
• A systematic review of association between use of hair products and benign and malignant gynecological conditions Cite
  Farooq H, Mhatre P, Aggarwal R, Robinson MT, Joseph E, Segars J, et al. A systematic review of association between use of hair products and benign and malignant gynecological conditions. European Journal of Obstetrics & Gynecology and Reproductive Biology. Elsevier BV; 2024; 295:160-171 10.1016/j.ejogrb.2024.02.012
• Clinicopathological and molecular pathological characteristics in tamoxifen‑related endometrial cancer Cite
  Saeki H, Horimoto Y, Hlaing M, Men Y, Rong L, Ishizuka Y, et al. Clinicopathological and molecular pathological characteristics in tamoxifen‑related endometrial cancer. Oncology Letters. Spandidos Publications; 2023; 27 10.3892/ol.2023.14142
• Assessment of ultrasonographic endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients receiving tamoxifen as hormonal adjuvant therapy Cite
  Babin M, Gluck O, Yeruham I, Keidar R, Kerner R, Weiner E, et al. Assessment of ultrasonographic endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients receiving tamoxifen as hormonal adjuvant therapy. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-3319956/v1
• Assessing the impact of contraceptive use on cancer risk among women of reproductive age – a systematic review Cite
  Jahanfar S, Mortazavi J, Lapidow A, Cu C, Abosy JA, Morris K, et al. Assessing the impact of contraceptive use on cancer risk among women of reproductive age – a systematic review. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-3191980/v1
• Risk of estrogen receptor–specific breast cancer by family history of estrogen receptor subtypes and other cancers Cite
  Wang Q, Zhang Y, Zeng E, Grassmann F, He W, Czene K. Risk of estrogen receptor–specific breast cancer by family history of estrogen receptor subtypes and other cancers. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2023; 10.1093/jnci/djad104
• Prospective Exploratory Study of the Effects of Postoperative Endocrine Medication on the Endometrium in Breast Cancer Patients Cite
  He Y, Li Y, Geng Y, Liu A, Gao F, Ji C, et al. Prospective Exploratory Study of the Effects of Postoperative Endocrine Medication on the Endometrium in Breast Cancer Patients. International Journal of General Medicine. Informa UK Limited; 2023; Volume 16:3677-3687 10.2147/ijgm.s417965
• Additive effects of 10-year exposures to PM2.5 and NO2 and primary cancer incidence in American older adults Cite
  Wei Y, Danesh Yazdi M, Ma T, Castro E, Liu CS, Qiu X, et al. Additive effects of 10-year exposures to PM2.5 and NO2 and primary cancer incidence in American older adults. Environmental Epidemiology. Ovid Technologies (Wolters Kluwer Health); 2023; 7:e265 10.1097/ee9.0000000000000265
• Evidence-based identification of breast cancer and associated ovarian and uterus cancer risk components in source waters from high incidence area in the Pearl River Basin, China Cite
  Peng S, Dong S, Gong C, Chen X, Du H, Zhan Y, et al. Evidence-based identification of breast cancer and associated ovarian and uterus cancer risk components in source waters from high incidence area in the Pearl River Basin, China. Science of The Total Environment. Elsevier BV; 2023;:166060 10.1016/j.scitotenv.2023.166060
• Evaluation of endometrial thickness in breast cancer patients with tamoxifen treatment – Difference between 2-dimensional ultrasonography and elastosonography Cite
  Jo HB, Lee HJ, Kim SC, Joo JK, Suh DS, Kim KH. Evaluation of endometrial thickness in breast cancer patients with tamoxifen treatment – Difference between 2-dimensional ultrasonography and elastosonography. Taiwanese Journal of Obstetrics and Gynecology. Elsevier BV; 2023; 62:547-552 10.1016/j.tjog.2023.04.004
• Risk of ER-specific breast cancer by family history of ER subtypes and other cancers Cite
  Wang Q, Zhang Y, Zeng E, Grassmann F, He W, Czene K. Risk of ER-specific breast cancer by family history of ER subtypes and other cancers. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2023; 10.1093/jnci/djad104
• Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort Cite
  Ramin C, Veiga LHS, Vo JB, Curtis RE, Bodelon C, Aiello Bowles EJ, et al. Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01647-y
• Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy Cite
  Nordenskjöld A, Fohlin H, Rosell J, Bengtsson N, Fornander T, Hatschek T, et al. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-2856174/v1
• Bisphenol B and bisphenol AF exposure enhances uterine diseases risks in mouse Cite
  Wu X, Yang X, Tian Y, Xu P, Yue H, Sang N. Bisphenol B and bisphenol AF exposure enhances uterine diseases risks in mouse. Environment International. Elsevier BV; 2023; 173:107858 10.1016/j.envint.2023.107858
• Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea Cite
  Kim D, Oh J, Seok J, Lee HS, Jeon S, Yoon CI. Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea. Diagnostics. MDPI AG; 2023; 13:792 10.3390/diagnostics13040792
• Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis Cite
  Allen I, Hassan H, Sofianopoulou E, Eccles D, Turnbull C, Tischkowitz M, et al. Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01610-x
• Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer Cite
  Ryu K, Kim MS, Lee JY, Nam S, Jeong HG, Kim T, et al. Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer. JAMA Network Open. American Medical Association (AMA); 2022; 5:e2243951 10.1001/jamanetworkopen.2022.43951
• Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study Cite
  Deng Z, Jones MR, Wang M, Visvanathan K. Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study. npj Breast Cancer. Springer Science and Business Media LLC; 2022; 8 10.1038/s41523-022-00447-5
• 398 Does tamoxifen therapy increases occurence of endometrium pathology? Cite
  Wojda K, Kalukiewicz A, Bobeff K, Sieroszewski P. 398 Does tamoxifen therapy increases occurence of endometrium pathology?. European Journal of Obstetrics & Gynecology and Reproductive Biology. Elsevier BV; 2022; 270:e104-e105 10.1016/j.ejogrb.2021.11.339
• Is screening for endometrial cancer necessary in asymptomatic women treated with tamoxifen for breast cancer? Cite
  Ju UC, Kang WD, Kim SM. Is screening for endometrial cancer necessary in asymptomatic women treated with tamoxifen for breast cancer?. European Journal of Gynaecological Oncology. IMR Press; 2022; 43:169-174 10.31083/j.ejgo4302022
• Abstract P3-12-25: Risk of second primary cancers after curative treatment of breast cancer: A Korean nationwide population-based study Cite
  Kim H, Kim SS, Lee JS, Yoon JS, Shin HJ, Lee JE, et al. Abstract P3-12-25: Risk of second primary cancers after curative treatment of breast cancer: A Korean nationwide population-based study. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P3-12-25-P3-12-25 10.1158/1538-7445.sabcs21-p3-12-25
• Chrysin attenuates estradiol-induced endometrial hyperplasia in rats via enhancing PPARα activity Cite
  Eid BG. Chrysin attenuates estradiol-induced endometrial hyperplasia in rats via enhancing PPARα activity. Environmental Science and Pollution Research. Springer Science and Business Media LLC; 2022; 10.1007/s11356-022-19206-x
• Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study Cite
  de Jonge MM, de Kroon CD, Jenner DJ, Oosting J, de Hullu JA, Mourits MJE, et al. Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2021; 113:1203-1211 10.1093/jnci/djab036
• Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer? Cite
  Lemon LS, Orr B, Modugno F, Buckanovich RJ, Coffman L, Edwards RP, et al. Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?. Gynecologic Oncology. Elsevier BV; 2022; 10.1016/j.ygyno.2022.01.022
• Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. Cite
  Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJ, Andrieu N, et al. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.. Apollo - University of Cambridge Repository; 2022; 10.17863/CAM.80147
• Hysteroscopic Endometrial Resection in Symptomatic Tamoxifen Treated Women for Breast Cancer Can Provide Both Definitive Diagnosis and Effective Long-term Therapy Cite
  Vilos GA, Alzawawi N, Oraif A, Lam JS, Badeghiesh A, Abu-Rafea B, et al. Hysteroscopic Endometrial Resection in Symptomatic Tamoxifen Treated Women for Breast Cancer Can Provide Both Definitive Diagnosis and Effective Long-term Therapy. Journal of Obstetrics and Gynaecology Canada. Elsevier BV; 2021; 10.1016/j.jogc.2021.12.007
• Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose–response meta-analysis of prospective studies Cite
  Byun D, Hong S, Ryu S, Nam Y, Jang H, Cho Y, et al. Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose–response meta-analysis of prospective studies. British Journal of Cancer. Springer Science and Business Media LLC; 2021; 10.1038/s41416-021-01625-1
• Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study Cite
  Zheng G, Sundquist J, Sundquist K, Ji J. Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study. BMC Cancer. Springer Science and Business Media LLC; 2021; 21 10.1186/s12885-021-08925-y
• Concomitant diagnosis of Endometrial and Breast Cancer - Does the sequence matters? Cite
  Stern T, Peleg Hasson S, Saad A, Levanon K, Michaan N, Laskov I, et al. Concomitant diagnosis of Endometrial and Breast Cancer - Does the sequence matters?. Gynecologic Oncology Reports. Elsevier BV; 2021;:100863 10.1016/j.gore.2021.100863
• Dietary Intake of Acrylamide and Risk of Breast, Endometrial, and Ovarian Cancers: A Systematic Review and Dose–Response Meta-analysis Cite
  Adani G, Filippini T, Wise LA, Halldorsson TI, Blaha L, Vinceti M. Dietary Intake of Acrylamide and Risk of Breast, Endometrial, and Ovarian Cancers: A Systematic Review and Dose–Response Meta-analysis. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2020; 29:1095-1106 10.1158/1055-9965.epi-19-1628
• Consumption of red meat and processed meat and cancer incidence: a systematic review and meta-analysis of prospective studies Cite
  Farvid MS, Sidahmed E, Spence ND, Mante Angua K, Rosner BA, Barnett JB. Consumption of red meat and processed meat and cancer incidence: a systematic review and meta-analysis of prospective studies. European Journal of Epidemiology. Springer Science and Business Media LLC; 2021; 10.1007/s10654-021-00741-9
• Amelioration of oestradiol valerate-induced endometrial hyperplasia in female rats by methanol fraction of Mangifera indica Linn. through modulation of oestrogen receptor signalling pathway Cite
  Olowofolahan AO, Tobih SE, Olorunsogo OO. Amelioration of oestradiol valerate-induced endometrial hyperplasia in female rats by methanol fraction of Mangifera indica Linn. through modulation of oestrogen receptor signalling pathway. Indian Journal of Physiology and Pharmacology. Scientific Scholar; 2021; 65:94-102 10.25259/ijpp_114_2021
• Effects of Hormone Therapy on survival, cancer, cardiovascular and dementia risks in 1.5 million women over age 65: a retrospective observational study Cite
  Baik S, McDonald C. Effects of Hormone Therapy on survival, cancer, cardiovascular and dementia risks in 1.5 million women over age 65: a retrospective observational study. Authorea, Inc.; 2021; 10.22541/au.161873076.60547427/v1
• Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: a nationwide data linkage study Cite
  Feng J, Qin X. Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: a nationwide data linkage study. Diabetes Research and Clinical Practice. Elsevier BV; 2021;:108755 10.1016/j.diabres.2021.108755
• Association of the Age at Menarche with Site-Specific Cancer Risks in Pooled Data from Nine Cohorts Cite
  Fuhrman BJ, Moore SC, Byrne C, Makhoul I, Kitahara CM, de González AB, et al. Association of the Age at Menarche with Site-Specific Cancer Risks in Pooled Data from Nine Cohorts. Cancer Research. American Association for Cancer Research (AACR); 2021; 10.1158/0008-5472.can-19-3093
• Estrogen Disrupting Pesticides in Nebraska Groundwater: Trends between Pesticide-contaminated Water and Estrogen-related Cancers in An Ecological Observational Study Cite
  New-Aaron M, Naveed Z, Rogan EG. Estrogen Disrupting Pesticides in Nebraska Groundwater: Trends between Pesticide-contaminated Water and Estrogen-related Cancers in An Ecological Observational Study. Water. MDPI AG; 2021; 13:790 10.3390/w13060790
• Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study Cite
  de Jonge MM, de Kroon CD, Jenner DJ, Oosting J, de Hullu JA, Mourits MJE, et al. Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2021; 10.1093/jnci/djab036
• Abstract PD12-07: Incidences of endometrial events and frequencies of endometrial invasive diagnostic procedures in breast cancer survivors on tamoxifen: A nationwide study Cite
  Choi S, Jeong Jh, Jung J, Lee YJ, Lee JW, Ko BS, et al. Abstract PD12-07: Incidences of endometrial events and frequencies of endometrial invasive diagnostic procedures in breast cancer survivors on tamoxifen: A nationwide study. Poster Spotlight Session Abstracts. American Association for Cancer Research; 2021; 10.1158/1538-7445.sabcs20-pd12-07
• Is ABO blood group a risk or prognostic factor for patients with endometrioid endometrial cancer? A retrospective analysis in Germany Cite
  Gitas G, Proppe L, Alkatout I, Tsolakidis D, Rody A, Kotanidis C, et al. Is ABO blood group a risk or prognostic factor for patients with endometrioid endometrial cancer? A retrospective analysis in Germany. Blood Transfusion. Edizioni SIMTI; 2020; 10.2450/2020.002-20
• Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen Cite
  Romero SA, Young K, Hickey M, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews. Wiley; 2020; 10.1002/14651858.cd007245.pub4
• Sugar-containing beverages and their association with risk of breast, endometrial, ovarian and colorectal cancers among Canadian women Cite
  Arthur RS, Kirsh VA, Mossavar-Rahmani Y, Xue X, Rohan TE. Sugar-containing beverages and their association with risk of breast, endometrial, ovarian and colorectal cancers among Canadian women. Cancer Epidemiology. Elsevier BV; 2020; 70:101855 10.1016/j.canep.2020.101855
• Protective Effects of Epigallocatechin Gallate (EGCG) on Endometrial, Breast, and Ovarian Cancers Cite
  Huang Y, Wang K, Chen H, Chiang Y, Hsia S. Protective Effects of Epigallocatechin Gallate (EGCG) on Endometrial, Breast, and Ovarian Cancers. Biomolecules. MDPI AG; 2020; 10:1481 10.3390/biom10111481
• Tamoxifen and Endometrial Cancer: A Janus-Headed Drug Cite
  Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers. MDPI AG; 2020; 12:2535 10.3390/cancers12092535
• Risk of primary urological and genital cancers following incident breast cancer: a Danish population-based cohort study Cite
  Sundbøll J, Farkas DK, Adelborg K, Schapira L, Tamang S, Nørgaard M, et al. Risk of primary urological and genital cancers following incident breast cancer: a Danish population-based cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 184:825-837 10.1007/s10549-020-05879-w
• Uterine cancer in breast cancer survivors: a systematic review Cite
  Wijayabahu AT, Egan KM, Yaghjyan L. Uterine cancer in breast cancer survivors: a systematic review. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:1-19 10.1007/s10549-019-05516-1
• Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies Cite
  Jeon J, Kim SE, Lee D, Choi D. Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 179:125-130 10.1007/s10549-019-05448-w
• The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans Cite
  Kim H, Choi DH, Park W, Im Y, Ahn JS, Park YH, et al. The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans. Hereditary Cancer in Clinical Practice. Springer Science and Business Media LLC; 2019; 17 10.1186/s13053-018-0103-3
• Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy Cite
  Fleming CA, Heneghan HM, O'Brien D, McCartan DP, McDermott EW, Prichard RS. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. British Journal of Surgery. Wiley; 2018; 105:1098-1106 10.1002/bjs.10899
• Multiple primary non-breast tumors in breast cancer survivors Cite
  Corso G, Veronesi P, Santomauro GI, Maisonneuve P, Morigi C, Peruzzotti G, et al. Multiple primary non-breast tumors in breast cancer survivors. Journal of Cancer Research and Clinical Oncology. Springer Science and Business Media LLC; 2018; 144:979-986 10.1007/s00432-018-2621-9
• Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis Cite
  Li Z, Wu Q, Song J, Zhang Y, Zhu S, Sun S. Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis. Hormones and Cancer. Springer Science and Business Media LLC; 2018; 9:197-204 10.1007/s12672-018-0330-0
• Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Womenʼs Health Initiative Observational Study Cite
  Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Womenʼs Health Initiative Observational Study. Menopause. Ovid Technologies (Wolters Kluwer Health); 2017; 25:11-20 10.1097/gme.0000000000000956
• Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study Cite
  Anveden Å, Taube M, Peltonen M, Jacobson P, Andersson-Assarsson JC, Sjöholm K, et al. Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study. Gynecologic Oncology. Elsevier BV; 2017; 145:224-229 10.1016/j.ygyno.2017.02.036
• Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630 Cite
  Potkul RK, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, et al. Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630. npj Breast Cancer. Springer Science and Business Media LLC; 2016; 2 10.1038/npjbcancer.2016.24
• Coffee and cancer risk: A meta-analysis of prospective observational studies Cite
  Wang A, Wang S, Zhu C, Huang H, Wu L, Wan X, et al. Coffee and cancer risk: A meta-analysis of prospective observational studies. Scientific Reports. Springer Science and Business Media LLC; 2016; 6 10.1038/srep33711
• Incidence of cancer in adolescent idiopathic scoliosis patients treated 25 years previously Cite
  Simony A, Hansen EJ, Christensen SB, Carreon LY, Andersen MO. Incidence of cancer in adolescent idiopathic scoliosis patients treated 25 years previously. European Spine Journal. Springer Science and Business Media LLC; 2016; 25:3366-3370 10.1007/s00586-016-4747-2
• Duration of Adulthood Overweight, Obesity, and Cancer Risk in the Women’s Health Initiative: A Longitudinal Study from the United States Cite
  Arnold M, Jiang L, Stefanick ML, Johnson KC, Lane DS, LeBlanc ES, et al. Duration of Adulthood Overweight, Obesity, and Cancer Risk in the Women’s Health Initiative: A Longitudinal Study from the United States. PLOS Medicine. Public Library of Science (PLoS); 2016; 13:e1002081 10.1371/journal.pmed.1002081
• Urolithin A suppresses the proliferation of endometrial cancer cells by mediating estrogen receptor-α-dependent gene expression Cite
  Zhang W, Chen J, Aguilera-Barrantes I, Shiau C, Sheng X, Wang L, et al. Urolithin A suppresses the proliferation of endometrial cancer cells by mediating estrogen receptor-α-dependent gene expression. Molecular Nutrition & Food Research. Wiley; 2016; 60:2387-2395 10.1002/mnfr.201600048
• Abstract 866: The proportion of breast and gynecological cancers in Australian women that can be attributed to the use of oral contraceptives and hormone replacement therapy Cite
  Jordan SJ, Wilson L, Whiteman D, Webb P. Abstract 866: The proportion of breast and gynecological cancers in Australian women that can be attributed to the use of oral contraceptives and hormone replacement therapy. Epidemiology. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-866
• Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen Cite
  Kesim MD, Aydin Y, Atis A, Mandiraci G. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric. Informa UK Limited; 2008; 11:252-257 10.1080/13697130802163168
• Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis Cite
  Liu J, Jiang W, Mao K, An Y, Su F, Kim BYS, et al. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 150:439-445 10.1007/s10549-015-3315-5
• Dietary Cadmium Exposure and Risk of Breast, Endometrial, and Ovarian Cancer in the Women’s Health Initiative Cite
  Adams SV, Quraishi SM, Shafer MM, Passarelli MN, Freney EP, Chlebowski RT, et al. Dietary Cadmium Exposure and Risk of Breast, Endometrial, and Ovarian Cancer in the Women’s Health Initiative. Environmental Health Perspectives. Environmental Health Perspectives; 2014; 122:594-600 10.1289/ehp.1307054
• Endometrial Cancer Incidence in Breast Cancer Patients Correlating with Age and Duration of Tamoxifen Use: a Population Based Study Cite
  Chen J, Kuo S, Liaw Y, Avital I, Stojadinovic A, Man Y, et al. Endometrial Cancer Incidence in Breast Cancer Patients Correlating with Age and Duration of Tamoxifen Use: a Population Based Study. Journal of Cancer. Ivyspring International Publisher; 2014; 5:151-155 10.7150/jca.8412
• Levonorgestrel Intrauterine System in Adjuvant Tamoxifen Treatment Cite
  Gizzo S, Di Gangi S, Bertocco A, Noventa M, Fagherazzi S, Ancona E, et al. Levonorgestrel Intrauterine System in Adjuvant Tamoxifen Treatment. Reproductive Sciences. Springer Science and Business Media LLC; 2013; 21:423-431 10.1177/1933719113503408
• Dietary Cadmium Intake and the Risk of Cancer: A Meta-Analysis Cite
  Cho YA, Kim J, Woo HD, Kang M. Dietary Cadmium Intake and the Risk of Cancer: A Meta-Analysis. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e75087 10.1371/journal.pone.0075087
• Endocrine Disrupting Activities of the Flavonoid Nutraceuticals Luteolin and Quercetin Cite
  Nordeen SK, Bona BJ, Jones DN, Lambert JR, Jackson TA. Endocrine Disrupting Activities of the Flavonoid Nutraceuticals Luteolin and Quercetin. Hormones and Cancer. Springer Science and Business Media LLC; 2013; 4:293-300 10.1007/s12672-013-0150-1
• Terpenoids from Zingiber officinale (Ginger) Induce Apoptosis in Endometrial Cancer Cells through the Activation of p53 Cite
  Liu Y, Whelan RJ, Pattnaik BR, Ludwig K, Subudhi E, Rowland H, et al. Terpenoids from Zingiber officinale (Ginger) Induce Apoptosis in Endometrial Cancer Cells through the Activation of p53. PLoS ONE. Public Library of Science (PLoS); 2012; 7:e53178 10.1371/journal.pone.0053178
• Dietary folates and cancer risk in a network of case–control studies Cite
  Tavani A, Malerba S, Pelucchi C, Dal Maso L, Zucchetto A, Serraino D, et al. Dietary folates and cancer risk in a network of case–control studies. Annals of Oncology. Elsevier BV; 2012; 23:2737-2742 10.1093/annonc/mds212
• Second malignancies after breast cancer: the impact of different treatment modalities Cite
  Kirova YM, De Rycke Y, Gambotti L, Pierga J, Asselain B, Fourquet A. Second malignancies after breast cancer: the impact of different treatment modalities. British Journal of Cancer. Springer Science and Business Media LLC; 2008; 98:870-874 10.1038/sj.bjc.6604241
• Risk of Primary Non–Breast Cancer After Female Breast Cancer by Age at Diagnosis Cite
  Mellemkjær L, Christensen J, Frederiksen K, Pukkala E, Weiderpass E, Bray F, et al. Risk of Primary Non–Breast Cancer After Female Breast Cancer by Age at Diagnosis. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2011; 20:1784-1792 10.1158/1055-9965.epi-11-0009
• Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age Cite
  Nsouli-Maktabi HH, Henson DE, Younes N, Young HA, Cleary SD. Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 129:963-969 10.1007/s10549-011-1560-9
• Abstract 3585: Second primary tumors after breast cancer: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) study Cite
  Ricceri F, Sacerdote C, Critelli R, Vineis P, Riboli E. Abstract 3585: Second primary tumors after breast cancer: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Epidemiology. American Association for Cancer Research; 2012; 10.1158/1538-7445.am2012-3585
• Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix Cite
  Biggar RJ, Wohlfahrt J, Melbye M. Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix. International Journal of Cancer. Wiley; 2011; 131:716-721 10.1002/ijc.26424
• Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Case–Control Study Cite
  Urban M, Banks E, Egger S, Canfell K, O'Connell D, Beral V, et al. Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Case–Control Study. PLoS Medicine. Public Library of Science (PLoS); 2012; 9:e1001182 10.1371/journal.pmed.1001182
• Molecular Pathways: Digoxin Use and Estrogen-Sensitive Cancers—Risks and Possible Therapeutic Implications: Figure 1. Cite
  Biggar RJ. Molecular Pathways: Digoxin Use and Estrogen-Sensitive Cancers—Risks and Possible Therapeutic Implications: Figure 1.. Clinical Cancer Research. American Association for Cancer Research (AACR); 2012; 18:2133-2137 10.1158/1078-0432.ccr-11-1389
• Cruciferous vegetables and cancer risk in a network of case–control studies Cite
  Bosetti C, Filomeno M, Riso P, Polesel J, Levi F, Talamini R, et al. Cruciferous vegetables and cancer risk in a network of case–control studies. Annals of Oncology. Elsevier BV; 2012; 23:2198-2203 10.1093/annonc/mdr604
• Hormonally Active Doses of Isoflavone Aglycones Promote Mammary and Endometrial Carcinogenesis and Alter the Molecular Tumor Environment in Donryu Rats Cite
  Kakehashi A, Tago Y, Yoshida M, Sokuza Y, Wei M, Fukushima S, et al. Hormonally Active Doses of Isoflavone Aglycones Promote Mammary and Endometrial Carcinogenesis and Alter the Molecular Tumor Environment in Donryu Rats. Toxicological Sciences. Oxford University Press (OUP); 2012; 126:39-51 10.1093/toxsci/kfs016
• Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies Cite
  Druesne-Pecollo N, Touvier M, Barrandon E, Chan DSM, Norat T, Zelek L, et al. Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 135:647-654 10.1007/s10549-012-2187-1
• Polyphenols, isothiocyanates, and carotenoid derivatives enhance estrogenic activity in bone cells but inhibit it in breast cancer cells Cite
  Veprik A, Khanin M, Linnewiel-Hermoni K, Danilenko M, Levy J, Sharoni Y. Polyphenols, isothiocyanates, and carotenoid derivatives enhance estrogenic activity in bone cells but inhibit it in breast cancer cells. American Journal of Physiology-Endocrinology and Metabolism. American Physiological Society; 2012; 303:E815-E824 10.1152/ajpendo.00142.2011
• Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation Cite
  Sreeja S, Santhosh Kumar TR, Lakshmi BS, Sreeja S. Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation. The Journal of Nutritional Biochemistry. Elsevier BV; 2012; 23:725-732 10.1016/j.jnutbio.2011.03.015
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Cite
  Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The Lancet. Elsevier BV; 2011; 378:771-784 10.1016/s0140-6736(11)60993-8
• Abstract 1812: Effects of vitamin D on obesity-induced increase in ER-positive and ER-negative mammary cancer in mice Cite
  Yu W, Kim D, Sumis A, Hilakivi-clarke L. Abstract 1812: Effects of vitamin D on obesity-induced increase in ER-positive and ER-negative mammary cancer in mice. Epidemiology. American Association for Cancer Research; 2011; 10.1158/1538-7445.am2011-1812
• Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis Cite
  Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1299-1309 10.1093/jnci/djr242
• Second cancers after breast cancer treatment Cite
  Matesich SMA, Shapiro CL. Second cancers after breast cancer treatment. Seminars in Oncology. Elsevier BV; 2003; 30:740-748 10.1053/j.seminoncol.2003.08.022
• Allium vegetables intake and endometrial cancer risk Cite
  Galeone C, Pelucchi C, Dal Maso L, Negri E, Montella M, Zucchetto A, et al. Allium vegetables intake and endometrial cancer risk. Public Health Nutrition. Cambridge University Press (CUP); 2009; 12:1576-1579 10.1017/s1368980008003820
• Circulating melatonin and the risk of breast and endometrial cancer in women Cite
  Viswanathan AN, Schernhammer ES. Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Letters. Elsevier BV; 2009; 281:1-7 10.1016/j.canlet.2008.11.002
• Lycopene and other carotenoids inhibit estrogenic activity of 17β-estradiol and genistein in cancer cells Cite
  Hirsch K, Atzmon A, Danilenko M, Levy J, Sharoni Y. Lycopene and other carotenoids inhibit estrogenic activity of 17β-estradiol and genistein in cancer cells. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2006; 104:221-230 10.1007/s10549-006-9405-7